NRAS and lung carcinoma: Later, Liu et al. documented that TTF-1 ablation conferred carboplatin resistance in the NRAS-mutated NCI-H2087 lung cancer cells5, whereas Maeda et al. observed that Ttf-1 sensitized the A549 lung cancer cells to cisplatin6.